

SAFETY DATA SHEET

SECTION 1. IDENTIFICATION

Product identifier used on the label

: **Tresiba® (insulin degludec injection)
FlexTouch(R) (100 U/ml, 200 U/ml) and Vial (100 U/ml)**

Other means of identification : N/Av

Recommended use of the chemical and restrictions on use

: Tresiba® is a long-acting basal insulin analog called insulin degludec. It is used to treat diabetes mellitus in patients one year of age or older.

Recommended restrictions: None known.

Chemical family

: Pure substance

Name, address, and telephone number of the supplier:

Novo Nordisk

800 Scudders Mill Road
Plainsboro, NJ, USA
08536

Supplier's Telephone # : 1-800-727-6500

24 Hr. Emergency Tel # : No information available.

Name, address, and telephone number of the manufacturer:

Refer to supplier

SECTION 2. HAZARDS IDENTIFICATION

Classification of the chemical

This material is not classified as hazardous under OSHA regulations (29 CFR Part 1910.1200).

Label elements

Hazard pictogram(s)

None required under U.S. OSHA Hazcom 2012 and Canadian WHMIS 2015 regulations.

Signal Word

Not required

Hazard statement(s)

Not required

Precautionary statement(s)

Not required

Other hazards

Other hazards which do not result in classification: May cause skin and respiratory irritation. May result in severe hypoglycemia. Inadvertent needle sticks may pose the risk of blood borne pathogens.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Mixture

<u>Chemical name</u>	<u>Common name and synonyms</u>	<u>CAS #</u>	<u>Concentration (% by weight)</u>
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	Not available.	84439-96-9	100.00

Inactive ingredients include: glycerol, metacresol, phenol, zinc, hydrochloric acid, and sodium hydroxide (for pH adjustment) and water for injection.

SAFETY DATA SHEET

SECTION 4. FIRST-AID MEASURES

Description of first aid measures

- Ingestion* : Do NOT induce vomiting. Have victim rinse mouth with water, then give one to two glasses of water to drink. Never give anything by mouth to an unconscious person. Seek medical attention if discomfort occurs.
- Inhalation* : If inhaled, move to fresh air. If breathing is difficult, give oxygen by qualified medical personnel only. If breathing has stopped, give artificial respiration. Obtain medical attention if symptoms develop and persist.
- Skin contact* : Wash with water and soap as a precaution. If irritation or symptoms develop, seek medical attention.
- Eye contact* : If in eyes, rinse with water for 15 minutes. Remove contact lenses if present and easy to do. Continue rinsing. If irritation persists, seek prompt medical attention.

Most important symptoms and effects, both acute and delayed

- : May cause an allergic skin reaction (e.g. swelling, rash and eczema). Causes damage to organs.(Circulatory system, Circulatory organs).

Indication of any immediate medical attention and special treatment needed

- : Treat symptomatically. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

SECTION 5. FIRE-FIGHTING MEASURES

Extinguishing media

- Suitable extinguishing media* : Use media suitable to the surrounding fire such as water fog or fine spray, alcohol foams, carbon dioxide and dry chemical.
- Unsuitable extinguishing media* : Do not use a solid water stream as it may scatter and spread fire.

Special hazards arising from the substance or mixture / Conditions of flammability

- : None known or reported by the manufacturer.

Flammability classification (OSHA 29 CFR 1910.106)

- : Not flammable.

Hazardous combustion products

- : irritating fumes and smoke

Special protective equipment and precautions for firefighters

- Protective equipment for fire-fighters* : Firefighters must use standard protective equipment including flame retardant coat, helmet with face shield, gloves, rubber boots, and in enclosed spaces, SCBA.
- Special fire-fighting procedures* : Firefighters should wear proper protective equipment and self-contained breathing apparatus with full face piece operated in positive pressure mode. Move containers from fire area if safe to do so. Water spray may be useful in cooling equipment exposed to heat and flame.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

- : Restrict access to area until completion of clean-up. Ensure clean-up is conducted by trained personnel only. Wear suitable protective equipment. Refer to protective measures listed in sections 7 and 8. Restrict access to area until completion of clean-up.

Environmental precautions : Ensure spilled product does not enter drains, sewers, waterways, or confined spaces.

Methods and material for containment and cleaning up

- : Ventilate area of release. Stop spill or leak at source if safely possible. Dike for water control. Contain and absorb spilled liquid with non-combustible, inert absorbent material (e.g. sand), then place absorbent material into a container for later disposal (see Section 13).

SAFETY DATA SHEET

Special spill response procedures

- : If a spill/release in excess of the EPA reportable quantity is made into the environment, immediately notify the national response center in the United States (phone: 1-800-424-8802).
 US CERCLA Reportable quantity (RQ): See section 15.

SECTION 7. HANDLING AND STORAGE

Precautions for safe handling

- : Prevent contact with needles used to administer Tresiba®. Use personal protective equipment as required. Tresiba® is for subcutaneous use only. Avoid breathing mist, vapors or spray. Avoid contact with eyes, skin and clothing. Wash thoroughly after handling. Launder contaminated clothing before reuse.

- Conditions for safe storage** : After first opening: Tresiba® should be kept at room temperature (below 86°F (30°C) or stored in the refrigerator (36 - 46°F (2 - 8 °C) away from direct heat and light. The opened (in-use) Tresiba® may be used up to 56 days (8 weeks) after being opened, if it is kept at room temperature or refrigerated (as indicated above). Tresiba® should not be used after the expiration date on the pens and vial.

- Incompatible materials** : Heat sources.

SECTION 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<u>Exposure Limits:</u>					
	<u>Chemical Name</u>	<u>ACGIH TLV</u>		<u>OSHA PEL</u>	
		<u>TWA</u>	<u>STEL</u>	<u>PEL</u>	<u>STEL</u>
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	N/Av	N/Av	N/Av	N/Av	

Exposure controls

Ventilation and engineering measures

- : Use in a well-ventilated area. Use general or local exhaust ventilation to maintain air concentrations below recommended exposure limits.

- Respiratory protection** : Use the indicated respiratory protection if the occupational exposure limit is exceeded and/or in case of product release (dust and/or fumes). Advice should be sought from respiratory protection specialists.

- Skin protection** : Wear protective gloves. Advice should be sought from glove suppliers.

- Eye / face protection** : Wear eye/face protection. Wear safety glasses with side shields (or goggles).

- Other protective equipment** : Wear sufficient clothing to prevent skin contact. Depending on conditions of use, an impervious apron should be worn. An eyewash station and safety shower should be made available in the immediate working area.

General hygiene considerations

- : Avoid contact with skin, eyes and clothing. Upon completion of work, wash hands before eating, drinking, smoking or use of toilet facilities. Handle in accordance with good industrial hygiene and safety practice. Contaminated work clothing must not be allowed out of the workplace.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Clear, colorless liquid.

Odour : Not available.

Odour threshold : Not available.

pH : approximately 7.6

Melting Point/Freezing point : Not available.

Initial boiling point and boiling range

: Not available

SAFETY DATA SHEET

Flash point : Not available.
Flashpoint (Method) : Not available.
Evaporation rate (BuAe = 1) : Not available.
Flammability (solid, gas) : Not applicable.
Lower flammable limit (% by vol.)
: Not applicable.
Upper flammable limit (% by vol.)
: Not applicable.
Oxidizing properties : Not applicable
Explosive properties : Not explosive
Vapour pressure : Not available.
Vapour density : Not available.
Relative density / Specific gravity
: Not available.
Solubility in water : Soluble
Other solubility(ies) : Not available.
Partition coefficient: n-octanol/water or Coefficient of water/oil distribution
: Not available.
Auto-ignition temperature : Not applicable.
Decomposition temperature : Not available.
Viscosity : Not available.
Volatiles (% by weight) : Not available.
Volatile organic Compounds (VOC's)
: Not available.
Absolute pressure of container
: Not applicable.
Flame projection length : Not applicable.
Other physical/chemical comments
: Molecular Weight: 6103.972 g/mol

SECTION 10. STABILITY AND REACTIVITY

Reactivity : This product is not reactive.
Chemical stability : Material is stable under normal conditions.
Possibility of hazardous reactions
: Under normal conditions of handling and storage, hazardous reactions will not occur.
Conditions to avoid : Avoid contact with incompatible materials.
Incompatible materials : See Section 7 (Handling and Storage) for further details.
Hazardous decomposition products
: None known, refer to hazardous combustion products in Section 5.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:

Routes of entry inhalation : YES
Routes of entry skin & eye : YES
Routes of entry Ingestion : YES
Routes of exposure skin absorption
: NO

SAFETY DATA SHEET

Potential Health Effects:

Signs and symptoms of short-term (acute) exposure

Sign and symptoms Inhalation

: May cause mild transient irritation.

Sign and symptoms ingestion

: Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhea.

Sign and symptoms skin

: Direct skin contact may cause slight or mild, transient irritation.

Sign and symptoms eyes

: Direct eye contact may cause slight or mild, transient irritation.

Potential Chronic Health Effects

: Frequent or prolonged contact may dry the skin, leading to discomfort and dermatitis.

Mutagenicity

: Not expected to be mutagenic in humans.

Carcinogenicity

: No components are listed as carcinogens by ACGIH, IARC, OSHA or NTP.

Reproductive effects & Teratogenicity

: Not expected to cause reproductive effects.

Sensitization to material

: Not expected to be a skin or respiratory sensitizer.

Specific target organ effects :

This material is not classified as hazardous under OSHA regulations (29CFR 1910.1200) (Hazcom 2012).

Not classified as specific target organ toxicity-repeated exposure.

Medical conditions aggravated by overexposure

: None known.

Synergistic materials

: Not available.

Toxicological data

: There is no available data for the product itself, only for the ingredients. See below for individual ingredient acute toxicity data.

<u>Chemical name</u>	<u>LC₅₀(4hr)</u> <u>inh, rat</u>	<u>LD₅₀</u>	
		<u>(Oral, rat)</u>	<u>(Rabbit, dermal)</u>
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	N/Av	N/Av	N/Av

Other important toxicological hazards

: None known or reported by the manufacturer.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

: Not classified for hazards to the environment. However, this does not exclude the possibility that large or frequent spills can have a harmful or damaging effect on the environment.

SAFETY DATA SHEET

Ecotoxicity data:

<u>Ingredients</u>	CAS No	Toxicity to Fish		
		LC50 / 96h	NOEC / 21 day	M Factor
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	84439-96-9	N/Av	N/Av	None.

<u>Ingredients</u>	CAS No	Toxicity to Daphnia		
		EC50 / 48h	NOEC / 21 day	M Factor
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	84439-96-9	N/Av	N/Av	None.

<u>Ingredients</u>	CAS No	Toxicity to Algae		
		EC50 / 96h or 72h	NOEC / 96h or 72h	M Factor
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	84439-96-9	N/Av	N/Av	None.

Persistence and degradability

: No data is available on the product itself.

Bioaccumulation potential

: No data is available on the product itself.

<u>Components</u>	<u>Partition coefficient n-octanol/water (log Kow)</u>	<u>Bioconcentration factor (BCF)</u>
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin) (CAS 84439-96-9)	N/Av	N/Av

Mobility in soil

: No data is available on the product itself.

Other Adverse Environmental effects

: No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

SECTION 13. DISPOSAL CONSIDERATIONS

Handling for Disposal

: Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Dispose of contents/container in accordance with local/regional/national/international regulations.

Methods of Disposal




: Dispose in accordance with all applicable federal, state, provincial and local regulations.

RCRA

: If this product, as supplied, becomes a waste in the United States, it may meet the criteria of a hazardous waste as defined under RCRA, Title 40 CFR 261. It is the responsibility of the waste generator to determine the proper waste identification and disposal method. For disposal of unused or waste material, check with local, state and federal environmental agencies.

SAFETY DATA SHEET

SECTION 14. TRANSPORT INFORMATION

Regulatory Information	UN Number	UN proper shipping name	Transport hazard class(es)	Packing Group	Label
49CFR/DOT	None.	Not regulated.	not regulated	none	
49CFR/DOT Additional information	None.				
IMDG	None.	Not regulated.	not regulated	none	
IMDG Additional information	None.				
ICAO/IATA	None.	Not regulated.	not regulated	none	
ICAO/IATA Additional information	None.				

Special precautions for user : None known or reported by the manufacturer.

Environmental hazards : This substance does not meet the criteria for an environmentally hazardous substance according to the IMDG Code. See ECOLOGICAL INFORMATION, Section 12.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
 : Not available.

SECTION 15 - REGULATORY INFORMATION

US Federal Information:

Components listed below are present on the following U.S. Federal chemical lists:

<u>Ingredients</u>	CAS #	TSCA Inventory	CERCLA Reportable Quantity(RQ) (40 CFR 117.302):	SARA TITLE III: Sec. 302, Extremely Hazardous Substance, 40 CFR 355:	SARA TITLE III: Sec. 313, 40 CFR 372, Specific Toxic Chemical	
					Toxic Chemical	de minimus Concentration
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	84439-96-9	NL	None.	None.	No	N/Ap

SARA TITLE III: Sec. 311 and 312, SDS Requirements, 40 CFR 370 Hazard Classes: None. Under SARA Sections 311 and 312, the EPA has established threshold quantities for the reporting of hazardous chemicals. The current thresholds are 500 pounds or the threshold planning quantity (TPQ), whichever is lower, for extremely hazardous substances and 10,000 pounds for all other hazardous chemicals.

US State Right to Know Laws:

The following chemicals are specifically listed by individual States:

SAFETY DATA SHEET

<u>Ingredients</u>	CAS #	California Proposition 65		State "Right to Know" Lists					
		Listed	Type of Toxicity	CA	MA	MN	NJ	PA	RI
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	84439-96-9	No		NS	NS	NS	NS	NS	NS

Canadian Information:

WHMIS information: Refer to Section 2 for a WHMIS Classification for this product.

International Information:

Components listed below are present on the following International Inventory list:

<u>Ingredients</u>	CAS #	European EINECs	Australia AICS	Philippines PICCS	Japan ENCS	Korea KECI/KECL	China IECSC	NewZealand IOC
Aqueous solution for injection, contains: B29 N(E) -hexadecandioyl-y-L-Glu desB30 Insulin degludec (rDNA origin)	84439-96-9		N/Av	N/Av	N/Av	N/Av	N/Av	N/Av

SECTION 16. OTHER INFORMATION

Legend

- : ACGIH: American Conference of Governmental Industrial Hygienists
- CAS: Chemical Abstract Services
- CERCLA: Comprehensive Environmental Response, Compensation, and Liability Act of 1980
- CFR: Code of Federal Regulations
- CSA: Canadian Standards Association
- DOT: Department of Transportation
- EPA: Environmental Protection Agency
- HMIS: Hazardous Materials Identification System
- HSDB: Hazardous Substances Data Bank
- IARC: International Agency for Research on Cancer
- Inh: Inhalation
- LC: Lethal Concentration
- LD: Lethal Dose
- MN: Minnesota
- N/Av: Not Applicable
- N/Av: Not Available
- NFPA: National Fire Protection Association
- NIOSH: National Institute of Occupational Safety and Health
- NJ: New Jersey
- NTP: National Toxicology Program
- OECD: Organisation for Economic Co-operation and Development
- OSHA: Occupational Safety and Health Administration
- PA: Pennsylvania
- PEL: Permissible exposure limit
- RCRA: Resource Conservation and Recovery Act
- RI: Rhode Island
- RTECS: Registry of Toxic Effects of Chemical Substances
- SARA: Superfund Amendments and Reauthorization Act
- STEL: Short Term Exposure Limit
- TLV: Threshold Limit Values
- TWA: Time Weighted Average
- WHMIS: Workplace Hazardous Materials Identification System

SAFETY DATA SHEET

References : 1. ACGIH, Threshold Limit Values for Chemical Substances and Physical Agents & Biological Exposure Indices for 2016
2. International Agency for Research on Cancer Monographs, searched 2017
3. Canadian Centre for Occupational Health and Safety, CCHInfoWeb databases, 2017(Chempendium, HSDB and RTECs).
4. Material Safety Data Sheets from manufacturer.
5. US EPA Title III List of Lists - 2017 version.
6. California Proposition 65 List - 2017 version.
7. OECD - The Global Portal to Information on Chemical Substances - eChemPortal,2017.

Preparation Date (mm/dd/yyyy)

: 08/20/2019

Other special considerations for handling

: Provide adequate information, instruction and training for operators.

<p><u>Prepared for:</u> Novo Nordisk 800 Scudders Mill Road Plainsboro, NJ 08536 1-800-727-6500 www.novonordisk-us.com</p>	
<p><u>Prepared by:</u> ICC The Compliance Center Inc. Telephone: (888) 442-9628 (U.S.); (888) 977-4834 (Canada) http://www.thecompliancecenter.com</p>	

DISCLAIMER

This Safety Data Sheet was prepared by ICC The Compliance Center Inc using information provided by / obtained from Novo Nordisk and CCOHS' Web Information Service. The information in the Safety Data Sheet is offered for your consideration and guidance when exposed to this product. ICC The Compliance Center Inc and Novo Nordisk expressly disclaim all expressed or implied warranties and assume no responsibilities for the accuracy or completeness of the data contained herein. The data in this SDS does not apply to use with any other product or in any other process.

This Safety Data Sheet may not be changed, or altered in any way without the expressed knowledge and permission of ICC The Compliance Center Inc and Novo Nordisk.

END OF DOCUMENT